This page shows 21shares XRP ETF (TOXR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of 21shares XRP ETF's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
21shares XRP ETF carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
21shares XRP ETF generates a -14.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.
Key Financial Metrics
Earnings & Revenue
21shares XRP ETF reported -$36.0M in net income in fiscal year 2025.
Cash & Balance Sheet
21shares XRP ETF had 12M shares outstanding in fiscal year 2025.
Margins & Returns
21shares XRP ETF's ROE was -14.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
TOXR Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$52.3M | N/A | $54.7M+169999.5% | $32K | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A |
TOXR Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|
| Total Assets | $142.2M-42.6% | $247.7M-11.5% | $280.0M | N/A | $209.5M |
| Current Assets | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $6K-81.6% | $35K-73.5% | $133K | N/A | $158K |
| Current Liabilities | N/A | N/A | N/A | N/A | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $142.1M-42.6% | $247.7M-11.5% | $279.9M+33.7% | $209.4M0.0% | $209.4M |
| Retained Earnings | -$99.7M-110.5% | -$47.3M-180.0% | $59.2M | N/A | -$11.3M |
TOXR Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q1'25 | Q4'24 |
|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -36.8% | N/A | 19.6%+19.5pp | 0.0% | N/A |
| Return on Assets | -36.8% | N/A | 19.5% | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A |
| Debt-to-Equity | 0.000.0 | 0.000.0 | 0.00 | N/A | 0.00 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A |